Zynerba Pharmaceuticals, Inc.

NasdaqCM:ZYNE Stock Report

Market Cap: US$65.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Zynerba Pharmaceuticals Future Growth

Future criteria checks 5/6

Zynerba Pharmaceuticals is forecast to grow earnings and revenue by 67.2% and 72% per annum respectively while EPS is expected to grow by 59% per annum.

Key information

67.2%

Earnings growth rate

59.02%

EPS growth rate

Pharmaceuticals earnings growth14.5%
Revenue growth rate72.0%
Future return on equityn/a
Analyst coverage

Low

Last updated16 Aug 2023

Recent future growth updates

Recent updates

Analysis Article • Mar 01

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 11

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 06

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Zynerba Pharmaceuticals (NASDAQ:ZYNE) said the U.S. Patent and Trademark Office issued a patent covering methods of treating Fragile X syndrome (FXS) with cannabidiol. The patent no. 11,458,110, titled 'Treatment of Fragile X Syndrome With Cannabidiol' will expire in 2038, is part of the Zynerba's intellectual property portfolio covering its transdermal cannabidiol product candidate Zygel, the company said in an Oct. 6 press release. FXS a genetic disorder due to changes in a gene called Fragile X Messenger Ribonucleoprotein 1 (FMR1) and causes developmental delays, learning disabilities and behavior problems, according to the U.S. CDC. ZYNE +4.99% to $0.77 premarket Oct. 6
Seeking Alpha • Aug 10

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Zynerba Pharmaceuticals press release (NASDAQ:ZYNE): Q2 GAAP EPS of -$0.24 misses by $0.01. As of June 30, 2022, cash and cash equivalents were $62.5 million, compared to $67.8 million as of December 31, 2021. Management believes that the Company’s cash and cash equivalents are sufficient to fund operations and capital requirements through the end of 2023 or into early 2024, after the expected availability of topline results from its confirmatory pivotal Phase 3 RECONNECT trial of Zygel in patients with FXS.
Analysis Article • Jul 22

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jul 21

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Zynerba Pharmaceuticals (NASDAQ:ZYNE) signed an equity purchase agreement for up to $20M with Chicago-based Lincoln Park Capital Fund. Under the agreement, the cannabinoid therapy maker will have the right, to sell up to $20M worth of common shares to LPC over the three year term of the contract. Zynerba said any stock sold will be at  market prices prevailing at that time. The company expects to use any net proceeds from the sale for working capital and general corporate purposes, including research and development expenses and capital expenditures. Zynerba noted that it may terminate the agreement at any time without any cost or penalty.
Analysis Article • Mar 23

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 02

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 27

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 23

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqCM:ZYNE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202548-24-34-323
12/31/202411-49-58-564
12/31/2023N/A-43-36-364
6/30/2023N/A-38-32-32N/A
3/31/2023N/A-37-31-31N/A
12/31/2022N/A-35-23-23N/A
9/30/2022N/A-36-25-25N/A
6/30/2022N/A-38-26-26N/A
3/31/2022N/A-38-25-25N/A
12/31/2021N/A-37-34-33N/A
9/30/2021N/A-38-33-33N/A
6/30/2021N/A-37-35-35N/A
3/31/2021N/A-47-39-39N/A
12/31/2020N/A-51-42-41N/A
9/30/2020N/A-52-42-42N/A
6/30/2020N/A-45-41-40N/A
3/31/2020N/A-36-37-36N/A
12/31/2019N/A-33-35-35N/A
9/30/20190-30-34-34N/A
6/30/20190-36-30-29N/A
3/31/20190-37-32-32N/A
12/31/20180-40-33-32N/A
9/30/2018N/A-40-33-33N/A
6/30/2018N/A-41-30-30N/A
3/31/2018N/A-37-29-29N/A
12/31/2017N/A-32-26-26N/A
9/30/2017N/A-31-25-25N/A
6/30/2017N/A-28-27-26N/A
3/31/2017N/A-26N/A-23N/A
12/31/20160-23N/A-20N/A
9/30/20160-22N/A-18N/A
6/30/20160-20N/A-16N/A
3/31/20160-15N/A-13N/A
12/31/20150-13N/A-10N/A
9/30/20150-9N/A-8N/A
6/30/20151-7N/A-6N/A
3/31/20151-7N/A-5N/A
12/31/20141-6N/A-4N/A
9/30/20141-5N/A-2N/A
12/31/20131-1N/A0N/A
12/31/20121-1N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYNE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: ZYNE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ZYNE is expected to become profitable in the next 3 years.

Revenue vs Market: ZYNE's revenue (72% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: ZYNE's revenue (72% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ZYNE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/12 16:10
End of Day Share Price 2023/10/10 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zynerba Pharmaceuticals, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Corey DavisCanaccord Genuity
Elemer PirosCantor Fitzgerald & Co.
Oren LivnatH.C. Wainwright & Co.